Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - Pharmaceutical News - FDA approves new generic valsartan to address shortages [Sport360] - March 23, 2019

Pharmacy News Article

 3/14/19 - FDA approves new generic valsartan to address shortages [Sport360]

The US Food and Drug Administration (FDA) has approved a new generic valsartan (Diovan; Alkem Laboratories Ltd) to help relieve recent shortages of the medicine.

Valsartan shortages have occurred as a result of multiple recalls of generic valsartan products from several manufacturers after they, and other angiotension II receptor blocker (ARB) medicines used to treat high blood pressure and heart failure, were found to be contaminated with nitrosamine impurities.

We know that the ongoing recalls to prevent certain lots of valsartan that contain unacceptable limits of impurities from reaching patients has resulted in a shortage of these important medicines, said FDA commissioner Scott Gottlieb, who is due to resign in April 2019.

He continued: So to address the public health consequences of these shortages, weve prioritised the review of generic applications for these valsartan products.

We hope that todays approval of this new generic will help reduce the valsartan shortage, and we remain committed to implementing measures to prevent the formation of these impurities during drug manufacturing processes for existing and future products.

For the approval of this new generic, the FDA evaluated the companys manufacturing processes to make sure that they used appropriate testing methods to demonstrate that it did not contain N-nitrosodiethylamine or N-nitrosodimethylamine (better known as NDEA and NDMA, respectively).

In July 2018, pharmacies across the EU were advised to recall all batches of valsartan-containing medicines made by Dexcel Pharma Ltd and Accord Healthcare (previously known as Actavis Group), after an impurity was unexpectedly identified as part of Zheijang Huahai Pharmaceuticals manufacturing process.

A further product recall for heart and blood pressure drug valsartan was then issued by the Medicines and Healthcare products Regulatory Agency in December 2018 to include batches of the medicine that contain drugs supplied by Teva and Mylan.

The FDA continues to investigate ARB medicines that contain nitrosamine impurities and fail to meet quality standards. It will continue to update the lists on its website of recalled valsartan, losartan and irbesartan products as more information becomes available from ongoing testing.

In the UK, the government has issued price concessions for 16 sartan medicines in February 2019.

(c) 2019 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Mar 26: Nutrigenomics - Nutritional Influences on the Genome
Mar 27: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Mar 28: Alternatives and Complements to Prescription Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement